Clinical Staging and Survival in Refractory Celiac Disease: A Single Center Experience

Alberto Rubio-Tapia, Darlene G. Kelly, Brian D. Lahr, Ahmet Dogan, Tsung Teh Wu, Joseph A Murray

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Background & Aims: Refractory celiac disease (RCD) occurs when both symptoms and intestinal damage persist or recur despite strict adherence to a gluten-free diet. In RCD, the immunophenotype of intraepithelial lymphocytes may be normal and polyclonal (RCD I) or abnormal and monoclonal (RCD II). The aim is to describe the clinical characteristics, treatment, and long-term outcome in a large single-center cohort of patients with RCD. Methods: We compared the clinical characteristics and outcome in 57 patients with RCD: 42 with RCD I and 15 with RCD II. Results: Fifteen of 57 patients died during follow-up (n = 8 with RCD I and n = 7 with RCD II), each within the first 2 years after RCD diagnosis. The overall 5-year cumulative survival is 70%, 80%, and 45% for the entire cohort, RCD I, and RCD II, respectively. The refractory state itself and enteropathy-associated T-cell lymphoma (EATL) were the most common causes of death, respectively. A new staging system is proposed based on the cumulative effect of 5 prognostic factors investigated at the time of the refractory state diagnosis: for patients in stages I, II, and III, the 5-year cumulative survival rate was 96%, 71%, and 19%, respectively (P < .0001). Conclusions: RCD is associated with high mortality with RCD II having an especially poor prognosis because of the development of EATL. A new staging model is proposed that may improve the precision of prognosis in patients with RCD.

Original languageEnglish (US)
Pages (from-to)99-107
Number of pages9
JournalGastroenterology
Volume136
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint

Celiac Disease
Survival
Enteropathy-Associated T-Cell Lymphoma
Gluten-Free Diet

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Clinical Staging and Survival in Refractory Celiac Disease : A Single Center Experience. / Rubio-Tapia, Alberto; Kelly, Darlene G.; Lahr, Brian D.; Dogan, Ahmet; Wu, Tsung Teh; Murray, Joseph A.

In: Gastroenterology, Vol. 136, No. 1, 01.2009, p. 99-107.

Research output: Contribution to journalArticle

Rubio-Tapia, Alberto ; Kelly, Darlene G. ; Lahr, Brian D. ; Dogan, Ahmet ; Wu, Tsung Teh ; Murray, Joseph A. / Clinical Staging and Survival in Refractory Celiac Disease : A Single Center Experience. In: Gastroenterology. 2009 ; Vol. 136, No. 1. pp. 99-107.
@article{cd125e2a44b54d19a2e5b9b2abadb5a8,
title = "Clinical Staging and Survival in Refractory Celiac Disease: A Single Center Experience",
abstract = "Background & Aims: Refractory celiac disease (RCD) occurs when both symptoms and intestinal damage persist or recur despite strict adherence to a gluten-free diet. In RCD, the immunophenotype of intraepithelial lymphocytes may be normal and polyclonal (RCD I) or abnormal and monoclonal (RCD II). The aim is to describe the clinical characteristics, treatment, and long-term outcome in a large single-center cohort of patients with RCD. Methods: We compared the clinical characteristics and outcome in 57 patients with RCD: 42 with RCD I and 15 with RCD II. Results: Fifteen of 57 patients died during follow-up (n = 8 with RCD I and n = 7 with RCD II), each within the first 2 years after RCD diagnosis. The overall 5-year cumulative survival is 70{\%}, 80{\%}, and 45{\%} for the entire cohort, RCD I, and RCD II, respectively. The refractory state itself and enteropathy-associated T-cell lymphoma (EATL) were the most common causes of death, respectively. A new staging system is proposed based on the cumulative effect of 5 prognostic factors investigated at the time of the refractory state diagnosis: for patients in stages I, II, and III, the 5-year cumulative survival rate was 96{\%}, 71{\%}, and 19{\%}, respectively (P < .0001). Conclusions: RCD is associated with high mortality with RCD II having an especially poor prognosis because of the development of EATL. A new staging model is proposed that may improve the precision of prognosis in patients with RCD.",
author = "Alberto Rubio-Tapia and Kelly, {Darlene G.} and Lahr, {Brian D.} and Ahmet Dogan and Wu, {Tsung Teh} and Murray, {Joseph A}",
year = "2009",
month = "1",
doi = "10.1053/j.gastro.2008.10.013",
language = "English (US)",
volume = "136",
pages = "99--107",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Clinical Staging and Survival in Refractory Celiac Disease

T2 - A Single Center Experience

AU - Rubio-Tapia, Alberto

AU - Kelly, Darlene G.

AU - Lahr, Brian D.

AU - Dogan, Ahmet

AU - Wu, Tsung Teh

AU - Murray, Joseph A

PY - 2009/1

Y1 - 2009/1

N2 - Background & Aims: Refractory celiac disease (RCD) occurs when both symptoms and intestinal damage persist or recur despite strict adherence to a gluten-free diet. In RCD, the immunophenotype of intraepithelial lymphocytes may be normal and polyclonal (RCD I) or abnormal and monoclonal (RCD II). The aim is to describe the clinical characteristics, treatment, and long-term outcome in a large single-center cohort of patients with RCD. Methods: We compared the clinical characteristics and outcome in 57 patients with RCD: 42 with RCD I and 15 with RCD II. Results: Fifteen of 57 patients died during follow-up (n = 8 with RCD I and n = 7 with RCD II), each within the first 2 years after RCD diagnosis. The overall 5-year cumulative survival is 70%, 80%, and 45% for the entire cohort, RCD I, and RCD II, respectively. The refractory state itself and enteropathy-associated T-cell lymphoma (EATL) were the most common causes of death, respectively. A new staging system is proposed based on the cumulative effect of 5 prognostic factors investigated at the time of the refractory state diagnosis: for patients in stages I, II, and III, the 5-year cumulative survival rate was 96%, 71%, and 19%, respectively (P < .0001). Conclusions: RCD is associated with high mortality with RCD II having an especially poor prognosis because of the development of EATL. A new staging model is proposed that may improve the precision of prognosis in patients with RCD.

AB - Background & Aims: Refractory celiac disease (RCD) occurs when both symptoms and intestinal damage persist or recur despite strict adherence to a gluten-free diet. In RCD, the immunophenotype of intraepithelial lymphocytes may be normal and polyclonal (RCD I) or abnormal and monoclonal (RCD II). The aim is to describe the clinical characteristics, treatment, and long-term outcome in a large single-center cohort of patients with RCD. Methods: We compared the clinical characteristics and outcome in 57 patients with RCD: 42 with RCD I and 15 with RCD II. Results: Fifteen of 57 patients died during follow-up (n = 8 with RCD I and n = 7 with RCD II), each within the first 2 years after RCD diagnosis. The overall 5-year cumulative survival is 70%, 80%, and 45% for the entire cohort, RCD I, and RCD II, respectively. The refractory state itself and enteropathy-associated T-cell lymphoma (EATL) were the most common causes of death, respectively. A new staging system is proposed based on the cumulative effect of 5 prognostic factors investigated at the time of the refractory state diagnosis: for patients in stages I, II, and III, the 5-year cumulative survival rate was 96%, 71%, and 19%, respectively (P < .0001). Conclusions: RCD is associated with high mortality with RCD II having an especially poor prognosis because of the development of EATL. A new staging model is proposed that may improve the precision of prognosis in patients with RCD.

UR - http://www.scopus.com/inward/record.url?scp=59849098316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59849098316&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2008.10.013

DO - 10.1053/j.gastro.2008.10.013

M3 - Article

C2 - 18996383

AN - SCOPUS:59849098316

VL - 136

SP - 99

EP - 107

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 1

ER -